Celgene pays AZ $450mm up front for rights to MedImmune's MEDI4736
Celgene Corp. licensed global rights to AstraZeneca PLC and MedImmune LLC's MEDI4736 (durvalumab), which it will develop and sell for blood cancers.
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.